Mindfulness program for chronic graft-versus-host disease
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether a mindfulness training program can help reduce symptoms like pain, fatigue, or distress in people living with chronic graft-versus-host disease (a long-term complication after a stem cell transplant). You would attend group sessions either in person or online.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with moderate or severe chronic graft-versus-host disease (cGvHD)
- You are willing to attend group sessions (in person or by video)
- You can read and understand English
- You have not already done 4 or more sessions of a similar mindfulness program
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells in the blood and tissues of people who have had a stem cell transplant. It aims to understand chronic graft-versus-host disease (GVHD), a common complication, so doctors can better detect and treat it.
This trial tests whether a mindfulness program, offered through faith communities, can help Black adult cancer survivors feel better and manage stress. It involves attending group sessions and completing online surveys.
This study tests an online mindfulness program (stress-reducing techniques) to help people with cancer who live in rural areas feel better emotionally. It is designed for those who are feeling significant distress.
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.